Page last updated: 2024-08-26

fotemustine and Benign Neoplasms, Brain

fotemustine has been researched along with Benign Neoplasms, Brain in 84 studies

Research

Studies (84)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	29 (34.52)	18.2507
2000's	25 (29.76)	29.6817
2010's	29 (34.52)	24.3611
2020's	1 (1.19)	2.80

Authors

Authors	Studies
Amato, G; Calabrò, L; Camerini, R; Chiarion-Sileni, V; Covre, A; Cutaia, O; Del Vecchio, M; Di Giacomo, AM; Ferrucci, PF; Giannarelli, D; Guida, M; Guidoboni, M; Maio, M; Mandalà, M; Marchetti, P; Quaglino, P; Valente, M	1
Baldaccini, D; Bazzoli, E; Bocci, G; Cantarella, M; Catania, F; Delishaj, D; Fabi, A; Fabrini, MG; Franchino, F; Gonnelli, A; Lolli, I; Lombardi, G; Molinari, A; Montrone, S; Morganti, R; Pace, A; Paiar, F; Pasqualetti, F; Pellerino, A; Rudà, R; Soffietti, R; Villani, V; Vivaldi, C; Zagonel, V	1
Buonerba, C; Cerbone, L; Cordua, N; De Placido, S; Di Lorenzo, G; Lamberti, G; Marinelli, A; Peluso, G	1
Addeo, R; Caraglia, M; Facchini, S; Luce, A; Zappavigna, S	1
Berardi, R; Burattini, L; Cascinu, S; Detti, B; Fabrini, MG; Iacovelli, R; Lolli, I; Perrone, F; Santoni, M; Savio, G; Scoccianti, S; Silvano, G	1
Gaviani, P; Lamperti, E; Salmaggi, A; Silvani, A; Simonetti, G	1
Bulzonetti, N; D'Elia, A; De Felice, F; Musio, D; Salvati, M; Tombolini, V	1
Bertero, L; Cassoni, P; Castiglione, A; Ciccone, G; Fabrini, MG; Lolli, I; Morra, I; Pasqualetti, F; Rudà, R; Soffietti, R; Trevisan, E	1
Bedane, C; Combemale, P; Cupissol, D; Derrey, S; Dygai-Cochet, I; Lamant, L; Leccia, MT; Lubrano, V; Mazeau-Woynar, V; Mirabel, X; Modiano, P; Mourrégot, A; Planchamp, F; Rougé Bugat, ME; Sassolas, B; Siegrist, S; Thariat, J; Tiffet, O; Truc, G; Verdoni, L	1
Bellu, L; Cecchin, D; Della Puppa, A; Farina, P; Lombardi, G; Pambuku, A; Zagonel, V	1
Della Puppa, A; Farina, P; Fiduccia, P; Lombardi, G; Pambuku, A; Roma, A; Zagonel, V; Zustovich, F	1
Carapella, CM; Carosi, MA; Cognetti, F; Fabi, A; Giannarelli, D; Marucci, L; Metro, G; Pace, A; Piludu, F; Pompili, A; Telera, S; Vaccaro, V; Vari, S; Vidiri, A; Villani, V	1
Artuso, S; Balestrieri, ML; Caraglia, M; De Rosa, G; Leonetti, C; Luce, A; Lusa, S; Porru, M; Salzano, G; Stoppacciaro, A; Zappavigna, S	1
Annesi, D; Ascierto, PA; Calabrò, L; Danielli, R; Del Vecchio, M; Di Giacomo, AM; Fonsatti, E; Giannarelli, D; Guidoboni, M; Maccalli, C; Maio, M; Maurichi, A; Orgiano, L; Parmiani, G; Pilla, L; Queirolo, P; Ridolfi, R; Santinami, M; Simeone, E; Spadola, G; Testori, A	1
Agolli, L; Caporello, P; Enrici, RM; Esposito, V; Falco, T; Lanzetta, G; Minniti, G; Osti, MF; Scaringi, C	1
Benavides, M; Berros, JP; Cano, JM; Ceballos, I; Covela, M; Fernández, I; Fuster, J; García Bueno, JM; García, A; Manneh, R; Moreno, V; Pérez-Segura, P; Quintanar, T; Sepúlveda, J; Vaz, MA	1
Agati, R; Brandes, AA; Caserta, C; Clavarezza, M; Eoli, M; Eusebi, V; Fabi, A; Finocchiaro, G; Franceschi, E; Lombardi, G; Maiello, E; Monteforte, M; Proietti, E; Reni, M; Zagonel, V	1
Bellu, L; D'Avella, D; Della Puppa, A; Farina, M; Fiduccia, P; Lombardi, G; Pambuku, A; Zagonel, V	1
Ammannati, F; Biti, G; Bordi, L; Borghesi, S; Detti, B; Iannalfi, A; Leonulli, BG; Martinelli, F; Meattini, I; Sardaro, A; Scoccianti, S	1
Cionini, L; Fabrini, MG; Lolli, I; Marsella, A; Perrone, F; Scotti, V; Silvano, G	1
Amistà, P; Bianchini, C; Blatt, V; Brandes, AA; Ermani, M; Faedi, M; Franceschi, E; Gardiman, M; Labianca, R; Reni, M; Santoro, A; Tosoni, A	1
Aitini, E; Ballardini, M; Bichisao, E; Fiorentini, G; Freschi, A; Guida, M; Michiara, M; Ridolfi, L; Ridolfi, R	1
Addeo, R; Caraglia, M; De Santi, MS; Del Prete, S	1
Carapella, CM; Carosi, M; Cognetti, F; Fabi, A; Lanzetta, G; Maschio, M; Metro, G; Pace, A; Russillo, M; Sperduti, I; Telera, S; Vidiri, A	1
Buonerba, C; De Placido, S; Di Lorenzo, G; Gallo, C; Marinelli, A; Romeo, V	1
Abbruzzese, A; Addeo, R; Caraglia, M; Carraturo, M; Cennamo, G; De Santi, MS; Del Prete, S; Faiola, V; Genovese, M; Montella, L; Parlato, C; Vincenzi, B	1
Adamo, V; Calista, F; Carrozza, F; Cigolari, S; Colucci, G; Ferraù, F; Galetta, D; Gebbia, V; Russo, P; Silvestris, N	1
Di Giacomo, AM; Maio, M; Margolin, KA	1
Botturi, A; Ferrari, D; Gaviani, P; Lamperti, E; Salmaggi, A; Silvani, A; Simonetti, G	1
Albanese, A; Anile, C; Balducci, M; Chiesa, S; D'Agostino, GR; De Bari, B; De Rose, F; Diletto, B; Fiorentino, A; Frascino, V; Manfrida, S; Mangiola, A; Mantini, G; Micciche', F; Morganti, AG; Valentini, V	1
Burattini, L; Cascinu, S; Onofri, A; Paccapelo, A; Santoni, M	1
Bonizzoni, E; Detti, B; Fabrini, MG; Lolli, I; Paccapelo, A; Perrone, F; Perrone, T; Santoni, M; Savio, G; Scoccianti, S; Silvano, G	1
Brocard, L; Daste, A; Durando, X; Gimbergues, P; Magné, N; Mansard, S; Thivat, E	1
Annesi, D; Ascierto, PA; Di Giacomo, AM; Ferrucci, PF; Fonsatti, E; Giannarelli, D; Maio, M; Marasco, A; Nicoletti, SV; Parmiani, G; Pilla, L; Queirolo, P; Ridolfi, R; Rivoltini, L; Santinami, M; Simeone, E; Testori, A	1
Garbe, C	1
Geissler, A; Gruss, C; Landthaler, M; Schalke, B; Stolz, W	1
Baruchel, S; Bouffet, E; Gammon, J; Grant, RM; Hargrave, DR; Tariq, N	1
Bensadoun, RJ; Bonneterre, ME; Bourdin, S; Bui, BN; Clavel, M; Cupissol, D; De Gislain, C; Delaunay, MM; Guillot, B; Hauschild, A; Lesimple, T; Mohr, P; Mornex, F; Mousseau, M; Thomas, L; Tilgen, W; Ulrich, J	1
Bensadoun, JR; Bonneterre, J; Bourdin, S; Clavel, M; Cupissol, D; de Gislain, C; Delaunay, MM; Guillot, B; Hauschild, A; Lesimple, T; Mohr, P; Mornex, F; Mousseau, M; Nguyen, BB; Thomas, L; Tilgen, W; Ulrich, J	1
Baumgartner, G; Budinsky, A; Czech, T; Dieckmann, K; Fazeny-Dörner, B; Gyries, A; Killer, M; Marosi, C; Muhm, M; Piribauer, M; Prayer, D; Rössler, K; Ungersböck, K; Veitl, M	1
Aamdal, S; Avril, MF; Bieber, T; Bonerandi, JJ; Bonneterre, J; Fra, J; Gilde, K; Gonzalez Larriba, JL; Grob, JJ; Guillem Porta, V; Hauschild, A; Kamanabrou, D; Menu, Y; Mohr, P; Neuber, K; Pehamberger, H; Saïag, P; Scherrer, A; Sufliarsky, J; Weichenthal, M	1
Eigentler, TK; Garbe, C	1
Friedlander, M; Kurtovic, J; Riordan, SM; Singh-Grewal, I; Webster, GJ	1
Bourg, V; Chanalet, S; Chatel, M; Fontaine, D; Frenay, M; Lebrun, C; Lonjon, M; Michiels, JF; Paquis, P; Ramaioli, A; Vandenbos, F	1
Akdemir, H; Altinbas, M; Cihan, Y; Coskun, HS; Er, O; Kaplan, B; Karahacioglu, E; Kontas, O; Menku, A; Ozkan, M	1
Carlander, B; Guillot, B; Khalil, Z; Pageot, N	1
Akimov, MA; Bogdanova, NV; Gershanovich, ML; Konstantinova, MM; Nosov, DA	1
Boiardi, A; Botturi, A; Eoli, M; Falcone, C; Filippini, G; Fiumani, A; Gaviani, P; Lamperti, E; Salmaggi, A; Silvani, A	1
Bajetta, E; Canova, S; Del Vecchio, M; Messina, A	1
Kobiakov, GL	1
Bröcker, EB; Engel, E; Gérard, B; Glabbeke, MV; Israels, P; Kennes, C; Kleeberg, UR; Lejeune, F; Lentz, MA; Tilgen, W	1
A'Hern, R; Atkinson, H; Chang, J; Gore, ME; Lorentzos, A	1
Astoul, P; Boutin, C; Juin, P; Muracciole, X; Orabona, P; Pignon, T; Ruggieri, S; Vialette, JP	1
Berille, J; Bertrand, P; Bizzari, JP; Cour, V; Gerard, B; Giroux, B; Khayat, D; Sarkany, M	1
Biron, P; Evene, E; Giroux, B; Gordon, B; Lucas, C; Mornex, F; Richards, R; Roux, N; Solere, P; Tranchand, B	1
Benoit, F; Bertheas, MF; Cambazard, F; Graille, MC; Guy, C; Lanthier, K; Perrot, JL	1
Berille, J; Brune, J; Cotto, C; Croisile, B; Giroux, B; Riou, R; Souquet, PJ; Trillet-Lenoir, V; Turjman, F	1
Anderson, CM; Buzaid, AC; Legha, SS	1
Bohndorf, W; Bröcker, EB; Engenhart, K; Flentje, M; Kämpgen, E; Messer, P; Tilgen, W; Trcka, J	1
Boland, I; Gouyette, A; Lacroix, C; Lellouch-Tubiana, A; Margison, GP; Morizet, J; Parker, F; Pierre-Kahn, A; Poullain, MG; Terrier-Lacombe, MJ; Vassal, G; Vénuat, AM; Watson, AJ	1
Breitbart, E; Makki, A; Mohr, P; Schadendorf, D	1
Bassères, N; Bizzari, JP; Bonerandi, JJ; Gérard, B; Grob, JJ; Richard, MA; Zarrour, H	1
Bröcker, EB; Göring, HD; Kämpgen, E; Kröning, Y; Trebing, D; Zierner, A	1
Bauer, J; Biollaz, J; Buclin, T; Decosterd, LA; Gander, M; Lejeune, F; Leyvraz, S; Marzolini, C; Shen, F	1
Bonerandi, JJ; Delaunay, M; Grob, JJ; Koeppel, MC; Laurans, R; Murraciole, X; Paul, K; Perragut, JC; Regis, J; Souteyrand, P; Wolkenstein, P	1
Dam-Hieu, P; Labat, JP; Lucas, B; Malhaire, JP; Person, H; Simon, H	1
Bryce, R; Etienne, MC; Ferrero, JM; Fischel, JL; Formento, P; Ilc, K; Milano, G	1
Belanich, M; Biollaz, J; Bonfanti, M; Colella, G; D'Incalci, M; Decosterd, L; Gander, M; Lejeune, F; Leyvraz, S; Liénard, D; Marzolini, C; Perey, L; Shen, F; Yarosh, D	1
Gademann, G; Gollnick, H; Ulrich, J	1
Frenay, M; Lebrun, C; Lonjon, M; Marcy, PY; Paquis, P	1
Bondiau, PY; Chatel, M; Frenay, M; Lebrun, C; Lonjon, M	1
Becker, JC; Bröcker, EB; Kämpgen, E; Terheyden, P	1
Bourg, V; Chichmanian, RM; Frenay, M; Lebrun, C; Thomas, P	1
Berger, E; Boiardi, A; Ciusani, E; Giroux, B; Lucas, C; Margison, G; Silvani, A; Watson, A	1
Chaitchik, S; Inbar, M; Kovner, F; Merimsky, O; Reider-Groswasser, I	1
Chaitchik, S; Gerard, B; Inbar, M; Merimsky, O	1
Avril, MF; Bertrand, P; Bizzari, JP; Cour, V; Gerard, B; Khayat, D	1
Boaziz, C; Breau, JL; Israël, L; Morère, JF	2
Chaitchik, S; Inbar, M; Merimsky, O; Reider-Groswasser, I	1
Aigner, K; Auclerc, G; Bizzari, JP; Borel, C; Bousquet, JC; Buthiau, D; Cohen-Alloro, G; Cour, V; Khayat, D; Weil, M	1
Aapro, M; Ardizzoni, A; Becquart, D; Calabresi, F; Dirix, L; Gerard, B; Wils, J	1
Avril, MF; Banzet, P; Bonerandi, JJ; Bonneterre, J; Fumoleau, P; Jacquillat, C; Kerbrat, P; Khayat, D; Namer, M; Weil, M	2

Reviews

12 review(s) available for fotemustine and Benign Neoplasms, Brain

Article	Year
Chemotherapy in the management of brain metastases: the emerging role of fotemustine for patients with melanoma and NSCLC. Expert opinion on drug safety, 2013, Volume: 12, Issue:5 Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Lung Neoplasms; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds	2013
An overview of fotemustine in high-grade gliomas: from single agent to association with bevacizumab. BioMed research international, 2014, Volume: 2014 Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Drug Therapy, Combination; Glioma; Humans; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Young Adult	2014
Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy. Seminars in oncology, 2010, Volume: 37, Issue:5 Topics: Antibodies, Monoclonal; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; CTLA-4 Antigen; Dacarbazine; Humans; Ipilimumab; Italy; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Survival Analysis; Temozolomide; United States	2010
[Therapeutic strategies and systemic treatment of brain melanoma metastases]. Bulletin du cancer, 2013, Jan-01, Volume: 100, Issue:1 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Humans; Immunotherapy; Indoles; Ipilimumab; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Palliative Care; Radiosurgery; Radiotherapy; Skin Neoplasms; Sulfonamides; Temozolomide; Vemurafenib	2013
[Therapy of malignant melanoma at the stage of distant metastasis]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2004, Volume: 55, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dacarbazine; Disease Progression; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Melanoma; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Palliative Care; Prognosis; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Skin Neoplasms; Temozolomide; Time Factors; Tomography, X-Ray Computed; Vindesine	2004
[Clinical significance of mustoforan in management of malignant glioma]. Voprosy onkologii, 2007, Volume: 53, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Disease-Free Survival; Female; Glioblastoma; Glioma; Humans; Lomustine; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm, Residual; Nitrosourea Compounds; Oligodendroglioma; Organophosphorus Compounds; Semustine; Survival Analysis; Treatment Outcome	2007
Fotemustine in the treatment of brain primary tumors and metastases. Cancer investigation, 1994, Volume: 12, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Glioma; Humans; Lung Neoplasms; Melanoma; Middle Aged; Multicenter Studies as Topic; Nitrosourea Compounds; Organophosphorus Compounds	1994
Systemic treatments for advanced cutaneous melanoma. Oncology (Williston Park, N.Y.), 1995, Volume: 9, Issue:11 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Humans; Immunotherapy, Active; Interferon-alpha; Interleukin-2; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Remission Induction; Skin Neoplasms; Survival Rate; Temozolomide	1995
Fotemustine: an overview of its clinical activity in disseminated malignant melanoma. Melanoma research, 1992, Volume: 2, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Lung Neoplasms; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Remission Induction; Vindesine	1992
[The blood-brain barrier: implications for chemotherapy in brain tumors]. Pathologie-biologie, 1991, Volume: 39, Issue:8 Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Drug Therapy, Combination; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Injections, Spinal; Methotrexate; Nitrosourea Compounds; Organophosphorus Compounds	1991
[Brain metastases of malignant melanomas]. Bulletin du cancer, 1991, Volume: 78, Issue:4 Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Dacarbazine; Humans; Interleukin-2; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Semustine	1991
Fotemustine (S 10036) in the intra-arterial treatment of liver metastasis from malignant melanoma. A phase II Study. American journal of clinical oncology, 1991, Volume: 14, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Drug Evaluation; Female; Hematologic Diseases; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Pilot Projects; Remission Induction	1991

Trials

38 trial(s) available for fotemustine and Benign Neoplasms, Brain

Article	Year
Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases. Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 09-01, Volume: 27, Issue:17 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Follow-Up Studies; Humans; Ipilimumab; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Nivolumab; Organophosphorus Compounds; Skin Neoplasms; Survival Rate; Time Factors; Young Adult	2021
High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients: A phase I/II trial. Medicine, 2018, Volume: 97, Issue:27 Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Glioblastoma; Humans; Incidence; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Temozolomide; Thrombocytopenia	2018
Safety of second-line chemotherapy with non-conventional fotemustine schedule in recurrent high grade gliomas: a single institution experience. Journal of neuro-oncology, 2013, Volume: 113, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate; Young Adult	2013
Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology). Journal of neuro-oncology, 2014, Volume: 116, Issue:3 Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Italy; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neurologic Examination; Nitrosourea Compounds; Organophosphorus Compounds; Retrospective Studies; Survival Analysis; Time Factors; Tumor Suppressor Proteins	2014
Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas. BioMed research international, 2014, Volume: 2014 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Disease-Free Survival; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Survival Rate	2014
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:4 Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biological Therapy; Brain Neoplasms; Female; Follow-Up Studies; Humans; Ipilimumab; Male; Melanoma; Middle Aged; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Prognosis; Skin Neoplasms; Survival Rate	2015
AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma. Neuro-oncology, 2016, Volume: 18, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Prognosis; Survival Rate	2016
Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience. Anti-cancer drugs, 2008, Volume: 19, Issue:6 Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Prognosis; Prospective Studies; Temozolomide	2008
A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma. Journal of neuro-oncology, 2009, Volume: 92, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds	2009
Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Recurrence; Temozolomide	2009
Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients. Melanoma research, 2009, Volume: 19, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Modality Therapy; Disease Progression; Female; Humans; Immunologic Factors; Immunotherapy; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Salvage Therapy; Skin Neoplasms; Survival Analysis	2009
Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study. Journal of neuro-oncology, 2010, Volume: 100, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Female; Glioma; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Promoter Regions, Genetic; Tumor Suppressor Proteins	2010
A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. Journal of neuro-oncology, 2011, Volume: 102, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Confidence Intervals; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Odds Ratio; Organophosphorus Compounds; Temozolomide; Time Factors; Tomography, X-Ray Computed	2011
Cisplatin, fotemustine and whole-brain radiotherapy in non-small cell lung cancer patients with asymptomatic brain metastases: a multicenter phase II study of the Gruppo Oncologico Italia Meridionale (GOIM 2603). Lung cancer (Amsterdam, Netherlands), 2011, Volume: 72, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Female; Humans; Italy; Lung Neoplasms; Male; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Treatment Outcome	2011
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. The Lancet. Oncology, 2012, Volume: 13, Issue:9 Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease-Free Survival; Female; Hematologic Diseases; Humans; Ipilimumab; Male; Melanoma; Middle Aged; Neoplasm Grading; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms	2012
Phase I study of fotemustine in pediatric patients with refractory brain tumors. Cancer, 2002, Sep-15, Volume: 95, Issue:6 Topics: Adolescent; Anemia; Antineoplastic Agents; Brain Neoplasms; Child; Child, Preschool; Ependymoma; Female; Humans; Infant; Injections, Intravenous; Male; Medulloblastoma; Neutropenia; Nitrosourea Compounds; Organophosphorus Compounds; Sarcoma; Thrombocytopenia; Treatment Outcome	2002
A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma research, 2003, Volume: 13, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Disease Progression; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Prospective Studies; Skin Neoplasms; Survival Rate; Treatment Outcome	2003
[Randomised phase III trial of fotemustine versus fotemustine plus whole brain irradiation in cerebral metastases of melanoma]. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2003, Volume: 7, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Diseases; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Disease Progression; Female; Humans; Life Tables; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Prospective Studies; Survival Analysis; Treatment Outcome	2003
Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Mar-15, Volume: 22, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Europe; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Quality of Life; Skin Neoplasms; Statistics, Nonparametric; Survival Analysis	2004
[Effectiveness and safety of combined mustoforan, cisplatin and tamoxifen for disseminated cutaneous melanoma (results of the IC4-10036-46-RU trial)]. Voprosy onkologii, 2005, Volume: 51, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Tamoxifen; Treatment Outcome	2005
Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. Journal of neuro-oncology, 2008, Volume: 87, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Procarbazine; Salvage Therapy; Temozolomide	2008
Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre phase II trial of the EORTC-Melanoma Cooperative Group (MCG). Melanoma research, 1995, Volume: 5, Issue:3 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Palliative Care; Treatment Outcome	1995
A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma. European journal of cancer (Oxford, England : 1990), 1994, Volume: 30A, Issue:14 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Female; Humans; Leukopenia; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Thrombocytopenia; Treatment Outcome	1994
Phase I pharmacokinetics study of high-dose fotemustine and its metabolite 2-chloroethanol in patients with high-grade gliomas. Cancer chemotherapy and pharmacology, 1993, Volume: 32, Issue:1 Topics: Adult; Antineoplastic Agents; Bone Marrow Transplantation; Brain Neoplasms; Ethylene Chlorohydrin; Female; Glioma; Half-Life; Humans; Male; Metabolic Clearance Rate; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds	1993
A phase II trial of fotemustine and cisplatin in central nervous system metastases from non-small cell lung cancer. European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Survival Rate	1996
Fotemustine given simultaneously with total brain irradiation in multiple brain metastases of malignant melanoma: report on a pilot study. Melanoma research, 1996, Volume: 6, Issue:5 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Pilot Projects; Radiotherapy Dosage; Treatment Outcome	1996
Combined treatment of stage IV melanoma patients with amifostine and fotemustine--a pilot study. Melanoma research, 1998, Volume: 8, Issue:2 Topics: Amifostine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Brain Neoplasms; Drug Administration Schedule; Humans; Leukopenia; Melanoma; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Pilot Projects; Skin Neoplasms; Thrombocytopenia	1998
Combined treatment with dacarbazine, cisplatin, fotemustine and tamoxifen in metastatic malignant melanoma. Melanoma research, 1998, Volume: 8, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Humans; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Survival Rate; Tamoxifen	1998
Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration. Cancer chemotherapy and pharmacology, 1998, Volume: 42, Issue:6 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Female; Glioma; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Temozolomide	1998
Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours. Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Glioma; Humans; Lymphocytes; Male; Melanoma; Middle Aged; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Organophosphorus Compounds; Temozolomide	1999
Sequential interferon-alpha2b, interleukin-2 and fotemustine for patients with metastatic melanoma. Melanoma research, 2000, Volume: 10, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease-Free Survival; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Skin Neoplasms; Survival Rate	2000
Fotemustine combined with procarbazine in recurrent malignant gliomas: a phase I study with evaluation of lymphocyte 06-alkylguanine-DNA alkyltransferase activity. Journal of neuro-oncology, 2001, Volume: 52, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Female; Glioma; Humans; Lymphocytes; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Organophosphorus Compounds; Procarbazine	2001
Fotemustine--an advance in the treatment of metastatic malignant melanoma. Melanoma research, 1992, Volume: 2, Issue:5-6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms	1992
Fotemustine: an overview of its clinical activity in disseminated malignant melanoma. Melanoma research, 1992, Volume: 2, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Lung Neoplasms; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Remission Induction; Vindesine	1992
Fotemustine (S 10036) in the intra-arterial treatment of liver metastasis from malignant melanoma. A phase II Study. American journal of clinical oncology, 1991, Volume: 14, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Drug Evaluation; Female; Hematologic Diseases; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Pilot Projects; Remission Induction	1991
Multicenter phase II trial of the single agent fotemustine in patients with advanced malignant melanoma. Annals of oncology : official journal of the European Society for Medical Oncology, 1991, Volume: 2, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Drug Evaluation; Europe; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms	1991
Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer, 1990, Nov-01, Volume: 66, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Drug Evaluation; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds	1990
Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma. Cancer chemotherapy and pharmacology, 1990, Volume: 25, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Drug Administration Schedule; Drug Evaluation; Female; Humans; Male; Melanoma; Middle Aged; Multicenter Studies as Topic; Nitrosourea Compounds; Organophosphorus Compounds; Remission Induction; Tomography, X-Ray Computed	1990

Other Studies

36 other study(ies) available for fotemustine and Benign Neoplasms, Brain

Article	Year
Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-Oncology. American journal of clinical oncology, 2018, Volume: 41, Issue:12 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Immunological; Bevacizumab; Brain Neoplasms; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Young Adult	2018
Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma. Journal of neuro-oncology, 2013, Volume: 113, Issue:3 Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate	2013
Low-dose fotemustine as second-line chemotherapy for recurrent glioblastoma multiforme. Anticancer research, 2013, Volume: 33, Issue:9 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease-Free Survival; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Recurrence	2013
[Management of patients with metastatic cutaneous melanoma: French national guidelines. French National Cancer Institute]. Annales de dermatologie et de venereologie, 2014, Volume: 141, Issue:2 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Management; France; Humans; Indoles; Ipilimumab; Liver Neoplasms; Lung Neoplasms; Melanoma; Molecular Targeted Therapy; Neoplasm Staging; Nitrosourea Compounds; Oncogenes; Organophosphorus Compounds; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Temozolomide; Vemurafenib	2014
The combination of carmustine wafers and fotemustine in recurrent glioblastoma patients: a monoinstitutional experience. BioMed research international, 2014, Volume: 2014 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds	2014
Medical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acid. Oncotarget, 2014, Nov-15, Volume: 5, Issue:21 Topics: Animals; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Cell Growth Processes; Cell Line, Tumor; Dacarbazine; Diphosphonates; Drug Delivery Systems; Drug Resistance, Neoplasm; Glioblastoma; Humans; Imidazoles; Male; Mice; Mice, Inbred Strains; Nanoparticles; Nitrosourea Compounds; Organophosphorus Compounds; Temozolomide; Transferrin; Tumor Burden; Xenograft Model Antitumor Assays; Zoledronic Acid	2014
Hypofractionated stereotactic radiotherapy in combination with bevacizumab or fotemustine for patients with progressive malignant gliomas. Journal of neuro-oncology, 2015, Volume: 122, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Female; Glioma; Humans; Karnofsky Performance Status; Male; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Radiation Dose Hypofractionation; Radiosurgery; Retrospective Studies	2015
GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2016, Volume: 18, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Retrospective Studies; Treatment Outcome; Young Adult	2016
Clinical outcome of an alternative fotemustine schedule in elderly patients with recurrent glioblastoma: a mono-institutional retrospective study. Journal of neuro-oncology, 2016, Volume: 128, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Administration Schedule; Female; Humans; Male; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Recurrence; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins	2016
Fotemustine and recurrent glioblastoma: possible new opportunities for an old drug. Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:5 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Glioblastoma; Humans; Methylation; Neoplasm Recurrence, Local; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Organophosphorus Compounds; Promoter Regions, Genetic; Randomized Controlled Trials as Topic	2009
Can high-dose fotemustine reverse MGMT resistance in glioblastoma multiforme? Journal of neuro-oncology, 2010, Volume: 100, Issue:2 Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Glioblastoma; Humans; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Radiotherapy, Conformal; Tumor Suppressor Proteins	2010
Lecture: fotemustine in brain tumors. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2011, Volume: 32 Suppl 2 Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Glioblastoma; Humans; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds	2011
Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study. Neuro-oncology, 2012, Volume: 14, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Modality Therapy; Dacarbazine; Dose Fractionation, Radiation; Feasibility Studies; Female; Glioblastoma; Humans; Male; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Palliative Care; Prognosis; Temozolomide	2012
Twice-daily dosing of temozolomide in combination with fotemustine for the treatment of patients with refractory glioblastoma. Anticancer research, 2012, Volume: 32, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Humans; Male; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Temozolomide	2012
A retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapy. Journal of translational medicine, 2012, May-14, Volume: 10 Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Retrospective Studies; Risk Factors; Temozolomide; Time Factors; Treatment Failure	2012
Ipilimumab with fotemustine in metastatic melanoma. The Lancet. Oncology, 2012, Volume: 13, Issue:9 Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Humans; Ipilimumab; Male; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms	2012
Severe neurological disabilities after complete remission of advanced malignant melanoma following fotemustine therapy in combination with total brain irradiation. Melanoma research, 2002, Volume: 12, Issue:4 Topics: Antineoplastic Agents, Alkylating; Atrophy; Brain; Brain Damage, Chronic; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dementia; Humans; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Palliative Care; Quality of Life; Radiotherapy, High-Energy; Remission Induction	2002
Survival improvement in patients with glioblastoma multiforme during the last 20 years in a single tertiary-care center. Wiener klinische Wochenschrift, 2003, Jun-24, Volume: 115, Issue:11 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Clinical Trials as Topic; Cobalt Radioisotopes; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Lomustine; Magnetic Resonance Imaging; Male; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Radiotherapy Dosage; Survival Analysis; Time Factors; Tomography, X-Ray Computed	2003
Prevention of hepatotoxicity but loss of antimelanoma effect with combined fotemustine and anti-oxidant treatment. Internal medicine journal, 2004, Volume: 34, Issue:5 Topics: Acetylcysteine; Adult; Antineoplastic Agents; Antioxidants; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Female; Humans; Liver; Lung Neoplasms; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Treatment Outcome	2004
Long-term outcome of oligodendrogliomas. Neurology, 2004, May-25, Volume: 62, Issue:10 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Craniotomy; Dacarbazine; Epilepsies, Partial; Etoposide; Female; Follow-Up Studies; Humans; Life Tables; Lomustine; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Nitrosourea Compounds; Oligodendroglioma; Organophosphorus Compounds; Procarbazine; Prognosis; Proportional Hazards Models; Radionuclide Imaging; Radiopharmaceuticals; Survival Analysis; Technetium Tc 99m Sestamibi; Temozolomide; Treatment Outcome; Vincristine	2004
Post-operative sequential chemo-radiotherapy in high-grade cerebral gliomas with fotemustine. Journal of chemotherapy (Florence, Italy), 2004, Volume: 16, Issue:3 Topics: Adult; Brain Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Probability; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Risk Assessment; Survival Analysis	2004
Neurological toxicity during metastatic melanoma treatment with fotemustine. Melanoma research, 2005, Volume: 15, Issue:6 Topics: Antineoplastic Agents; Brain Neoplasms; Female; Humans; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds	2005
Impressive objective response in a patient with extensive metastatic melanoma including the brain. Melanoma research, 2007, Volume: 17, Issue:5 Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Female; Humans; Lung Neoplasms; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Tomography, X-Ray Computed	2007
[Association of radiation- and fotemustine-therapy in the management of brain metastases from non-small-cell cancers of the lung]. Bulletin du cancer. Radiotherapie : journal de la Societe francaise du cancer : organe de la societe francaise de radiotherapie oncologique, 1994, Volume: 81, Issue:1 Topics: Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Prognosis; Survival Analysis	1994
[Acquired myelodysplastic syndromes after treatment of melanoma with fotemustine and dacarbazine]. Annales de dermatologie et de venereologie, 1995, Volume: 122, Issue:10 Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Fatal Outcome; Female; Humans; Melanoma; Middle Aged; Myelodysplastic Syndromes; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms	1995
Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity. Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:2 Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cerebellar Neoplasms; DNA Glycosylases; DNA Repair; Drug Screening Assays, Antitumor; Female; Glioma; Humans; Male; Medulloblastoma; Mice; Middle Aged; N-Glycosyl Hydrolases; Neoplasm Transplantation; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Organophosphorus Compounds; Transplantation, Heterologous; Tumor Cells, Cultured	1998
Effective combined immunochemotherapy with dinitrochlorobenzene and fotemustine in skin and brain metastases of melanoma. Melanoma research, 1998, Volume: 8, Issue:4 Topics: Allergens; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dermatitis, Allergic Contact; Dinitrochlorobenzene; Humans; Immunotherapy; Irritants; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Remission Induction; Salvage Therapy; Skin Neoplasms	1998
Radiosurgery without whole brain radiotherapy in melanoma brain metastases. Club de Cancérologie Cutanée. European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Humans; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Palliative Care; Radiosurgery; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome	1998
[Fotemustine (Muphoran) in 22 patients with relapses of high-grade cerebral gliomas]. Bulletin du cancer, 1999, Volume: 86, Issue:3 Topics: Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds	1999
Cytotoxic effects of two gamma linoleic salts (lithium gammalinolenate or meglumine gammalinolenate) alone or associated with a nitrosourea: an experimental study on human glioblastoma cell lines. Anti-cancer drugs, 1999, Volume: 10, Issue:4 Topics: Antineoplastic Agents; Brain Neoplasms; Cell Survival; Drug Interactions; Drug Screening Assays, Antitumor; gamma-Linolenic Acid; Glioblastoma; Humans; Lithium Compounds; Meglumine; Nitrosourea Compounds; Organophosphorus Compounds; Tumor Cells, Cultured	1999
Management of cerebral metastases from malignant melanoma: results of a combined, simultaneous treatment with fotemustine and irradiation. Journal of neuro-oncology, 1999, Volume: 43, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Retrospective Studies; Survival Analysis	1999
[Chemotherapy of malignant inoperable gliomas. The association of fotemustine-cisplatine-etoposide as neoadjuvants]. Revue neurologique, 2000, Volume: 156, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Cisplatin; Etoposide; Female; Glioma; Humans; Male; Middle Aged; Neoadjuvant Therapy; Nitrosourea Compounds; Organophosphorus Compounds; Treatment Outcome	2000
Up-front chemotherapy with fotemustine (F) / cisplatin (CDDP) / etoposide (VP16) regimen in the treatment of 33 non-removable glioblastomas. European journal of cancer (Oxford, England : 1990), 2000, Volume: 36, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Etoposide; Female; France; Glioblastoma; Humans; Male; Middle Aged; Neoadjuvant Therapy; Nitrosourea Compounds; Organophosphorus Compounds; Survival Rate; Treatment Outcome	2000
Nitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity. Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:2 Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Drug Interactions; Epilepsy; Etoposide; Female; Glioma; Hematologic Tests; Humans; Male; Middle Aged; Neutropenia; Nitrosourea Compounds; Organophosphorus Compounds; Retrospective Studies; Thrombocytopenia; Valproic Acid	2001
Cerebral metastatic melanoma: correlation between clinical and CT findings. Melanoma research, 1992, Volume: 2, Issue:5-6 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Tomography, X-Ray Computed	1992
Fotemustine with or without dacarbazine for brain metastases of malignant melanoma. European journal of cancer (Oxford, England : 1990), 1991, Volume: 27, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Evaluation; Humans; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds	1991